Introduction {#Sec1}
============

Coronavirus disease 2019 (COVID-19) may cause severe respiratory distress and has been associated with enhanced morbidity and mortality \[[@CR1]\]. There is increasing evidence that COVID-19 may induce severe acute cardiac injury with alterations of cardiac function and elevation of myocardial injury markers including troponin and brain-natriuretic peptide (BNP) \[[@CR2]--[@CR4]\]. Severe compromise of cardiac function and/or pre-existing cardiovascular disease have been reported to be associated with poor prognosis \[[@CR5], [@CR6]\]. Thus, the European Society of Cardiology and the American College of Cardiology strongly recommend a careful cardiologic assessment of patients who present with symptomatic COVID-19 infection \[[@CR7], [@CR8]\]. Electrocardiographic, echocardiographic and cardiac-specific laboratory parameters are cornerstones to define cardiac injury during infectious disease including COVID-19 \[[@CR9]--[@CR11]\]. In the present study, we report the cardiac-specific findings in the first collective of patients admitted and treated at our university hospital.

Methods {#Sec2}
=======

Study design and participants {#Sec3}
-----------------------------

For this consecutive, prospective study, patients were enrolled from February to March 2020 and routine blood samples were collected at hospital admission. We performed transthoracic echocardiography as well as electrocardiography (ECG) within 24 h after admission. Written informed consent was obtained from all non-ventilated patients. Patients were admitted to the University Hospital of Tübingen, Germany. We included 123 consecutive patients diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 was diagnosed via RNA detection from nasopharyngeal secretions with real-time reverse transcriptase polymerase chain reaction. This study was approved by the institutional ethics committee (238/2018BO2) and complies with the declaration of Helsinki and the good clinical practice guidelines \[[@CR12]--[@CR14]\].

Transthoracic echocardiography {#Sec4}
------------------------------

Transthoracic echocardiography (TTE) was performed in patients with symptomatic and verified COVID-19 infection within 24 h after hospital admission. Left ventricular ejection fraction (LVEF), right ventricular function (RV-function), valve defects as well as pericardial effusion (PE) were evaluated. LVEF was determined using Simpson's biplane method of discs by manual planimetry of the endocardial border in end-diastolic and end-systolic frames as well as by visual assessment \[[@CR15]\]. Impaired LVEF was defined as a systolic ejection fraction ≤ 50% \[[@CR16]\]. RV-function was determined by visual assessment, measurement of tricuspid annular plane systolic excursion (TAPSE), and right ventricular fractional area change (RV-FAC). TAPSE was assessed by placing an M-mode cursor through the lateral tricuspid valve annulus in the apical four-chamber view and measuring the total systolic excursion distance of the tricuspid annulus. TAPSE ≥ 20 mm was considered as an indicator for normal RV-function \[[@CR16]\]. Right ventricular dysfunction was considered present when RV-FAC was \< 35% \[[@CR16]\]. Mitral regurgitation was determined by left atrium jet area and width of vena contracta \[[@CR17]\]. Aortic stenosis was measured via continuity equitation and planimetry of valve area \[[@CR18]\]. Aortic valve regurgitation was determined using jet/left ventricular outflow tract (LVOT) width, diastolic flow reversal in proximal descending aorta as well as pressure half time (PHT) \[[@CR19]\]. Finally, tricuspid regurgitation was defined using central jet area and width of vena contracta \[[@CR17]\]. When possible, the pulmonary artery pressure was estimated by determining the flow velocity when a tricuspid regurgitation was present \[[@CR20]\].

12-Channel ECG and laboratory parameters {#Sec5}
----------------------------------------

12-Channel ECG was registered according to standard procedure. Peripheral venous blood was analysed for laboratory parameters including C-reactive protein, troponin I, NT pro-BNP, and [d]{.smallcaps}-dimers.

Clinical follow-up {#Sec6}
------------------

30-Day follow-up was available for all patients after study inclusion for the primary endpoint all-cause death.

Statistical analysis {#Sec7}
--------------------

All statistical analyses were performed using SPSS version 26.0 (SPSS Inc., Chicago IL, USA). Normally distributed data were compared using Student's *T* test. Non-normally distributed data were compared performing Mann--Whitney *U* Test. Mean values are presented as mean ± standard deviation. Median values are presented as median and 25th/75th percentiles. Cross-tabulations with Chi-square tests were performed descriptively to show the number of endpoint distribution. For censored data, Kaplan--Meier curves with log rank tests were determined. Multiple Cox-regression analysis was applied to analyse associations of impaired myocardial function with the endpoint mortality after adjustment for epidemiological factors.

Results {#Sec8}
=======

Baseline characteristics are presented in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. Table [1](#Tab1){ref-type="table"} shows baseline characteristics for the overall collective (*n* = 123) whereas baseline characteristics in Table [2](#Tab2){ref-type="table"} are stratified according to mortality. We were able to provide echocardiographic data for 98 patients (79.7%), electrocardiographic data for 115 patients (93.5%) and laboratory parameters for all COVID-19 patients.Table 1Baseline characteristics of the overall cohort (*n* = 123)Age, years (mean ± SD)68 (± 15)Male, *n* (%)77 (62.6)Body mass index (mean ± SD)28 (± 5)**Cardiovascular risk factors,*n*(%)**Arterial hypertension86 (69.9)Dyslipidemia46 (37.4)Diabetes mellitus30 (24.4)Current smokers1 (0.8)Obesity24 (19.5)Atrial fibrillation28 (22.8)Known CAD28 (22.8)Chronic kidney disease14 (11.4)**Echocardiography**Left ventricular function, %, mean (± SD)57 (8)Left ventricular hypertrophy, *n* (%)69 (74.2)Visually estimated normal right ventricular function, *n* (%)81 (86.2)Visually estimated impaired right ventricular function, *n* (%)13 (13.7)Right ventricular dilatation, *n* (%)46 (48.9)TAPSE, mm, mean (± SD)22 (± 5)TAPSE \< 20 mm, *n* (%)17 (17.3)RV-FAC (%)37 (± 8.9)RV pressure, mmHg, mean (± SD)29 (± 11)Aortic stenosis \> 1, *n* (%)4 (5.7)Aortic regurgitation \> 1, *n* (%)10 (11.5)Mitral regurgitation \> 1, *n* (%)24 (26.7)Tricuspid regurgitation \> 1, *n* (%)30 (30.6)Pericardial effusion, *n* (%)45 (48.9)**Electrocardiography**Rate, bpm, mean (± SD)85 (± 23)Sinus rhythm, *n* (%)80 (69.6)QRS, ms, mean (± SD)94 (± 22)Regular R progression, *n* (%)54 (47)Right bundle branch block, *n* (%)4 (3.5)Left bundle branch block, *n* (%)1 (0.9)PQ segment, ms, mean (± SD)172 (± 94)QTc, ms, mean (± SD)445 (± 33)Negative *T* wave, *n* (%)13 (11.3)ST segment depression, *n* (%)1 (0.9)ST segment elevation, *n* (%)0 (0.0)**Laboratory values at admission, median (25th/75th percentile)**Leucocytes, 1000/µl6.6 (4.4/9.2)Lymphocytes, 1000/µl0.8 (0.6/1.1)Creatinin, mg/dl0.9 (0.7/1.3)GFR, ml/m^2^74 (49/91)D-dimers, µg/dl1.2 (0.7/2.8)C-reactive protein, mg/dl8.1 (2.6/15.5)Procalcitonin, ng/ml0.1 (0.1/0.7)Troponin I, ng/dl16 (5/33)NT pro-BNP, ng/l445 (139/2714)CK, U/l152 (76/320)AST, U/l43 (27/63)ALT, U/l34 (21/49)LDH, U/l334 (242/437)**Medication at admission,*n*(%)**Oral anticoagulation15 (12.2)ACEi/ARB60 (48.8)Aldosterone inhibitors15 (12.2)Diuretics40 (32.5)Calcium channel blockers26 (21.1)Beta blockers43 (35.0)Statins41 (33.3)ASA27 (22.0)P2Y12 inhibitors3 (2.4)Table 2Baseline characteristics stratified according to mortalityNon-survivorsSurvivors*p* value(*n* = 16)(*n* = 107)Age, years (mean ± SD)73 (± 16)67 (± 15)0.235Male, *n* (%)12 (75.0)65 (60.7)0.272Body mass index (mean ± SD)30 (± 5)28 (± 5)0.183**Cardiovascular risk factors,*n*(%)**Arterial hypertension12 (75.0)74 (69.2)0.635Dyslipidemia3 (18.8)43 (40.2)0.098Diabetes mellitus5 (31.3)25 (23.4)0.743Current smokers0 (0.0)1 (0.9)0.707Obesity2 (12.5)22 (20.6)0.549trial fibrillation4 (25.0)24 (22.4)0.834Known CAD6 (37.5)22 (20.6)0.340Chronic kidney disease2 (12.5)12 (11.2)0.880**Echocardiography**Left ventricular function, %, mean (± SD)49 (± 12)58 (± 6)**0.034**Left ventricular hypertrophy, *n* (%)10 (90.9)59 (67.8)0.162Visually estimated normal right ventricular function, *n* (%)6 (54.5)75 (86.2)**0.001**Visually estimated impaired right ventricular function, *n* (%)5 (45.5)8 (9.2)**0.001**Right ventricular dilatation, *n* (%)5 (45.5)41 (47.1)0.762TAPSE, mm, mean (± SD)21 (± 6)23 (± 5)0.397TAPSE \< 20 mm, *n* (%)4 (36.4)4 (4.6)0.076RV-FAC (%)30 (± 10.0)38 (± 8.5)**0.008**RV pressure, mmHg, mean (± SD)30 (± 11)29 (± 11)0.712Aortic stenosis \> 1, *n* (%)1 (9.1)3 (3.4)0.388Aortic regurgitation \> 1, *n* (%)0 (0.0)10 (11.5)0.431Mitral regurgitation \> 1, *n* (%)3 (27.3)21 (24.1)0.495Tricuspid regurgitation \> 1, *n* (%)7 (63.6)23 (23.4)**0.018**Pericardial effusion, *n* (%)4 (36.4)41 (47.1)0.520**Electrocardiography**Rate, bpm, mean (± SD)93 (± 25)84 (± 22)0.268Sinus rhythm, *n* (%)9 (75)71 (81.6)0.476QRS, ms, mean (± SD)101 (± 14)93 (± 22)0.134Regular *R* progression, *n* (%)4 (33.3)50 (57.5)0.065Right bundle branch block, *n* (%)1 (8.3)3 (5.3)0.606Left bundle branch block, *n* (%)0 (0.0)1 (1.1)0.704PQ segment, ms, mean (± SD)155 (± 24)174 (± 99)0.175QTc, ms, mean (± SD)451 (± 33)444 (± 34)0.457Negative *T* wave, *n* (%)1 (8.3)12 (21.1)0.896ST segment depression, *n* (%)0 (0.0)1 (1.8)0.896ST segment elevation, *n* (%)0 (0.0)0 (0.0)0.668**Laboratory values at admission, median (25th/75th percentile)**Leucocytes, 1000/µl8.5 (6.6/1.3)6.3 (4.3/8.7)**0.016**Lymphocytes, 1000/µl0.7 (0.4/1.2)0.8 (0.6/1.1)0.428Creatinin, mg/dl1.1 (0.8/2.3)0.9 (0.7/1.3)0.260GFR, ml/m^2^69 (22/87)74 (51/91)0.321[d]{.smallcaps}-dimers, µg/dl2.6 (1.2/21.0)1.1 (0.6/2.7)**0.003**C-reactive protein, mg/dl19.9 (10.9/30.0)6.7 (2.3/14.6)**0.001**Procalcitonin, ng/ml0.8 (0.1/2.6)0.1 (0.1/0.5)**0.002**Troponin I, ng/dl24 (16/120)14 (5/29)**0.023**NT pro-BNP, ng/l1992 (416/7719)377 (132/1914)**0.041**CK, U/l485 (295/1332)124 (73/258)**\< 0.001**AST, U/l89 (54/136)39 (24/56)**\< 0.001**ALT, U/l47 (19/84)32 (21/46)0.115LDH, U/l478 (380/547)311 (229/414)**0.001Medication at admission,*n*(%)**Oral anticoagulation0 (0.0)15 (14.0)0.138ACEi/ARB8 (50.0)52 (48.6)0.433Aldosterone inhibitors4 (25.0)11 (10.3)**0.041**Diuretics5 (31.2)35 (32.7)0.745Calcium channel blockers3 (18.8)23 (21.5)0.952Beta blockers6 (37.5)37 (34.6)0.462Statins3 (18.8)38 (35.5)0.314ASA3 (18.8)24 (22.4)0.984P2Y12 inhibitors0 (0)3 (2.8)0.532A *p*-value \<0.05 was considered as statistically significant

The overall 30-day mortality of our hospitalized patients was 13% (*n* = 16). The majority of deceased patients received ventilation therapy for acute or progressive pulmonary failure and developed multiorgan failure refractory to intensive care treatment (*n* = 14). 56 patients required ICU treatment, 49 patients mechanical ventilation, and 6 patients ECMO therapy. 6 patients were transiently treated for acute cardiovascular complains on the IMC-chest pain unit, and 61 patients were treated on a regular ward. 22 patients were dialyzed during hospital stay. Mean hospital stay was 7.4 days (± 5.4), whereas in non-survivors, days from admission to death were 10.2 (± 7.5). Patients with impaired LVEF, impaired RV-function, and a tricuspid regurgitation \> 1 had a significantly higher mortality than patients with normal LVEF, normal RV-function, and mild tricuspid regurgitation ≤ 1 (Fig. [1](#Fig1){ref-type="fig"}). Patients with impaired LVEF and RV-function showed a significantly worse cumulative event-free survival compared to patients with normal LVEF and RV-function \[log rank \< 0.001 and log rank \< 0.001 for all-cause death, respectively (Fig. [1](#Fig1){ref-type="fig"})\]. Furthermore, tricuspid regurgitation \> 1 was associated with a significantly worse cumulative event-free survival \[log rank 0.011 for all-cause death (Fig. [1](#Fig1){ref-type="fig"})\].Fig. 1Upper row: Kaplan--Meier curves showing cumulative event-free survival for the endpoint all-cause death stratified according to LVEF, RV function and TR. Lower row: bar diagrams showing distribution of LVEF, RV-function and TR between survivors and non-survivors. *TR* tricuspid regurgitation

Moreover, in non-survivors leucocyte count, [d]{.smallcaps}-dimers, C-reactive protein, procalcitonin, troponin-I, NT pro-BNP, CK, AST, and LDH levels were significantly higher and treatment with aldosterone antagonists was significantly more frequent when compared to survivors (Table [2](#Tab2){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}). LVEF at admission did not correlate with D-dimers (rho = − 0.155, *p* = 0.116). LVEF at admission was, however, significantly associated with troponin I and NT pro-BNP (rho = − 0.367, *p* \< 0.001 and rho = − 0.485, *p* \< 0.001, respectively). Furthermore, RV-FAC at admission did not significantly correlate with [d]{.smallcaps}-dimers (rho = − 0.103, *p* = 0.321) but was significantly associated with troponin I and NT pro-BNP (rho = − 0.442, *p* \< 0.001 and rho = − 0.304, *p* = 0.006, respectively). Cumulative event-free survival was lower by trend in patients with reduced RV-FAC when compared to those with normal RV-FAC (Log rank = 0.280 for RV-FAC cut off 35% and Log rank = 0.056 for RV-FAC cut off 30%, respectively).Fig. 2Laboratory values at admission stratified according to survivors and non-survivors

Cox-regression analysis with mortality as dependent and age, arterial hypertension, diabetes mellitus type 2, LVEF, RV-function, and tricuspid regurgitation \> 1 as independent variables revealed that besides diabetes mellitus, LVEF was significantly and independently associated with all-cause mortality (Table [3](#Tab3){ref-type="table"}). Due to the low event rate multivariate analysis warrants, however, cautious interpretation.Table 3Cox-regression analysis with forward variable selection with mortality as dependent and age, arterial hypertension, diabetes mellitus type 2, LVEF, RV-function, and tricuspid regurgitation \> 1 as independent variablesVariableHR (95% CI)*p* valueDiabetes mellitus type 23.65 (1.06--12.63)**0.041**LVEF12.19 (2.87--51.83)**0.001**

Discussion {#Sec9}
==========

The main findings of the present study are: (i) in a consecutive collective of symptomatic COVID-19-positive patients with respiratory distress, impaired systolic left and right ventricular function as well as relevant tricuspid regurgitation are associated with 30-day all-cause mortality. (ii) Elevated levels of myocardial distress markers (troponin-I, NT pro-BNP) are associated with poor prognosis in COVID-19 patients.

Our findings in line with previous reports confirm that cardiac injury is a major concern and occurs frequently in COVID-19 patients with respiratory failure. Severe respiratory distress has been considered to be the main cause of COVID-19-associated deaths. Recently, Shi et al. have found that 7.2% of hospitalized COVID-19 patients develop cardiac injury, which increases up to approximately 20% when patients are referred to intensive care units \[[@CR21]\]. Patients with pre-existing cardiovascular disease seem to be more susceptible to COVID-19 than those lacking this condition \[[@CR22]\].

At present, the pathophysiological mechanisms of COVID-19 and cardiac injury and heart failure are poorly understood. However, it seems likely as known for other infectious diseases that COVID-19-induced systemic inflammatory responses may contribute to myocardial failure especially in patients with known heart disease \[[@CR23], [@CR24]\]. Further, our findings indicate that right ventricular stress as indicated by the presence of the right ventricular failure and a relevant tricuspid regurgitation might be a consequence of COVID-19-induced pulmonary distress with development of elevation of the pulmonary artery pressure \[[@CR25]\]. This explanation is further strengthened by the observation that the majority of severely affected COVID-19 patients reveal elevated levels of NT pro-BNP levels indicative of acute myocardial stress \[[@CR26]\]. We could, however, not show significant associations between elevated pulmonary artery pressure and mortality in COVID-19 patients. In the present study, we applied conventional echocardiographic diagnosis without performing LV and RV strain analyses, which may be more adequate to detect subtle changes in myocardial function. However, at the time being, we were not able to analyse the echocardiographic strain for this first COVID-19 wave at our institution due to logistical challenges.

At present, we do not have a causal therapy for COVID-19 affected patients. However, our data and an increasing number of reports strongly suggest that the thorough assessment of cardiac function is an absolute requirement in COVID-19 patient care. After the published statement of the German Cardiac Society in March 2020, we continued and initiated guideline-recommended HF therapy in every patient with impaired LV- and/or RV-function as well as elevated NT pro-BNP plasma levels. The type of medical HF therapy included ARBs, ACE, aldosterone antagonists and ß-Blockers. None of the 123 patients received Sacubitril/Valsartan. A rigorous treatment of cardiac dysfunction according to the well-established and recommended international guidelines should be a cornerstone for patients with COVID-19. Turning away from effective treatment options may do further harm to affected COVID-19 patients. On the other hand, following our cardiology guidelines is at present one of the few possibilities to save lives. Thus, a formation of a competent Cardio-COVID-19 team is one major critical measure in fighting the threatening disease.

Conclusions {#Sec10}
===========

Cardiac failure is associated with poor prognosis in patients COVID-19 infection. A comprehensive assessment of cardiac function is required in patients care with symptoms of acute COVID-19 infection.
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